All In Biotech

Free tool

FAERS Monitor: Izervay

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 217225 or its brand name (Izervay, Avacincaptad Pegol Sodium). Reports on generic versions are filed under their own applications.

Reports

352

Serious

141

40% of reports

Hospitalization

6

Death reported

5

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • visual impairment26
  • intercepted product preparation error25
  • eye pain24
  • no adverse event24
  • needle issue23
  • off label use22
  • vision blurred22
  • syringe issue18
  • endophthalmitis16
  • product temperature excursion issue16
  • choroidal neovascularisation15
  • intraocular pressure increased15
  • eye inflammation14
  • blindness transient13
  • inappropriate schedule of product administration13

Reports by year received

View as table
YearReports
20235
2024110
2025114
2026123

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,807 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
choroidal neovascularisationSignal151064.3645.714,629
product temperature excursion issueSignal16186.7115.62,764
endophthalmitisSignal16159.898.92,363
intercepted product preparation errorSignal25121.683.32,867
blindness transientSignal13105.561.91,242
eye inflammationSignal1487.852.51,115
intraocular pressure increasedSignal1570.242.8955
syringe issueSignal1861.539.21,012
needle issueSignal2347.231.8996
eye painSignal2425.417.3540
visual impairmentSignal2612.58.7266
vision blurredSignal229.66.4162
no adverse eventSignal247.95.4139
inappropriate schedule of product administrationSignal134.32.530
off label use221.51.03

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.